Feed aggregator

Get to Know Norman Sussman, Chief Medical Officer at DURECT

Biospace news - Thu, 04/22/2021 - 02:00
BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.

Antibody Structure: All You Ever Wanted – and Needed – to Know

Biospace news - Thu, 04/22/2021 - 02:00
Simply put, an antibody is a large, Y-shaped blood protein produced by plasma cells that the immune system uses to take down pathogens like bacteria – and of course, viruses like SARS-CoV-2.

Tips for Demonstrating Leadership Skills on Your Resume

Biospace news - Thu, 04/22/2021 - 02:00
Regardless of the field that you work in, incorporating leadership skills on your resume is a crucial step in making sure your application is noticed by employers.

Why Having Adaptive Leadership Skills Is a Perk for Your Life Sciences Career

Biospace news - Thu, 04/22/2021 - 02:00
Why are adaptive leaders so useful? And is this a quality that will benefit your life sciences career? Let’s explore this concept.

Three Elements to Consider When Looking for Your Dream Job

Biospace news - Thu, 04/22/2021 - 02:00
Do you know what your “dream job” is? Would you be able to identify it if you had multiple job offers? Many people are in search of a dream job, but don’t really know how to find one and what makes it different than other average job opportunities.

Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001

World Pharma News - Wed, 04/21/2021 - 10:00
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it is now focusing on bilateral discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC).

FDA Asks Emergent to Temporarily Halt J&J COVID-19 Vaccine Ingredient Production

Biospace news - Wed, 04/21/2021 - 02:00
The U.S. FDA has requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson COVID-19 vaccine at their facility in Baltimore.

Roche Quietly Pulls Two Phase II COVID-19 Studies in Q1

Biospace news - Wed, 04/21/2021 - 02:00
The Swiss pharma giant quietly announced the cuts this morning in a breakdown of its first quarterly financial report.

Clearing Up a Misconception: COVID-19 Vaccines Don't Cause Shingles

Biospace news - Wed, 04/21/2021 - 02:00
A small study by researchers in Israel published in the journal Rheumatology identified six cases of patients developing herpes zoster rashes (shingles) after receiving the Pfizer-BioNTech vaccine.

Money on the Move: April 14-20

Biospace news - Wed, 04/21/2021 - 02:00
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.

AAN Annual Meeting Highlights: Sleep Quality, Migraine, COVID-19 Interferon Treatment and More

Biospace news - Wed, 04/21/2021 - 02:00
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.

Let’s Get to Know Paula Ragan, CEO and President of X4 Pharmaceuticals

Biospace news - Wed, 04/21/2021 - 02:00
BioSpace spoke with Paula Ragan, CEO and President of X4 Pharmaceuticals, a company focused on restoring healthy immune system function in people with rare diseases.

Beam’s New CRISPR Base Editing Tool Targets Sickle Cell Mutation

Biospace news - Wed, 04/21/2021 - 02:00
Beam Therapeutics has recently unveiled a new CRISPR base editing tool to target sickle cell mutations, a promising approach that holds substantial clinical value for patients with these blood disorders.

Mission Bio Launches Assay Development Service for Single Cell Multiomics

Biospace news - Wed, 04/21/2021 - 02:00
Mission Bio just launched its Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on its existing products.

Versant Raises $560 Million For New Early-Stage Biotech Fund

Biospace news - Wed, 04/21/2021 - 02:00
The fund will seek to invest in at least 20 startups located in the U.S., Canada, and Europe.

Researchers Get to Work on Opioid Overuse Vaccine With $25 Million NIH Grant

Biospace news - Wed, 04/21/2021 - 02:00
A $25 million grant from the National Institutes of Health Helping to End Addiction Long-term Initiative (HEAL) is funding new research to develop a vaccine that may help patients overcome their addiction to opioids, a class of highly addictive pain medications.

Nearly $1.3 Billion in OWS Funds Went to ApjJect Systems for Syringes Yet to Be Authorized

Biospace news - Wed, 04/21/2021 - 02:00
ApiJect’s syringe is designed to be prefilled with a dose of a vaccine before it is shipped out to be used by doctors, pharmacists, hospitals, and many of the vaccination centers set up across the country. NBC noted that the prefilled technology had not been approved in the U.S.

IPO Flurry Continues: Talaris, Gyroscope, Sagimet All Plan to Go Public

Biospace news - Wed, 04/21/2021 - 02:00
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.

4 Ways to Stay Productive if You’ve Been Furloughed

Biospace news - Wed, 04/21/2021 - 02:00
If you’ve been furloughed, it’s normal to feel some apprehension, fear and/or doubt about your employment. These are four ways to stay productive if you’ve been furloughed.

Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19

World Pharma News - Tue, 04/20/2021 - 12:00
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.

Researchers from the Wellcome Sanger Institute, Newcastle University, University College London, University of Cambridge, EMBL's European Bioinformatics Institute (EMBL-EBI) and their collaborators within the Human Cell Atlas initiative, found raised levels of specific immune cells in asymptomatic people.